Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Magnetic susceptibility is predictive of future clinical severity in Parkinson’s disease

George EC Thomas, Naomi Hannaway, Angelika Zarkali, Karin Shmueli, Rimona S Weil
doi: https://doi.org/10.1101/2023.07.12.23292555
George EC Thomas
1Dementia Research Centre, UCL Institute of Neurology, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: george.thomas.14{at}ucl.ac.uk
Naomi Hannaway
1Dementia Research Centre, UCL Institute of Neurology, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Angelika Zarkali
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karin Shmueli
2Department of Medical Physics and Biomedical Engineering, UCL, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rimona S Weil
1Dementia Research Centre, UCL Institute of Neurology, London, UK
3Wellcome Centre for Human Neuroimaging, UCL, London, UK
4Movement Disorders Consortium, UCL, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Dementia is common in Parkinson’s disease, but there is wide variation in its timing. With the emergence of disease modifying treatments in neurodegeneration, there is increasing need to detect and treat disease at the earliest stages and to monitor disease progression. A critical gap in Parkinson’s disease is the lack of quantifiable markers of progression, and methods to identify early stages. Until recently, MRI has had limited sensitivity to detect or track changes relating to Parkinson’s dementia, but advanced techniques, especially quantitative magnetic susceptibility mapping (QSM) which is sensitive to brain tissue iron, show potential for these purposes. So far, QSM, applied to cognition in Parkinson’s, has only been investigated in detail in cross-sectional cohorts. Here we present a longitudinal study throughout the brain using QSM in Parkinson’s disease. We included 59 Parkinson’s patients (with no dementia at study onset), and 22 controls, at baseline and after 3-year follow-up. Participants underwent detailed assessments of motor and cognitive severity at both timepoints. We found that increased magnetic susceptibility values in right temporal cortex and right putamen in patients were associated with poorer cognition at baseline. Strikingly, increased baseline susceptibility values within right temporal cortex, nucleus basalis of Meynert and putamen in patients were associated with greater cognitive severity after 3-year follow-up; and increased baseline susceptibility in basal ganglia, substantia nigra, red nucleus, insular cortex and dentate nucleus in patients were associated with greater motor severity after 3-year follow-up. We further found that after 3-years, increased follow-up susceptibility in these regions was associated with increased follow-up cognitive and motor severity, with further involvement of hippocampus relating to cognitive severity. However, region of interest analyses revealed that, in cortical regions, increases in paramagnetic susceptibility relating to iron could not alone explain the associations with increased clinical severity that were observed; and, similar to other studies, we did not find consistent increases in susceptibility within the 3-year follow-up period. Our study suggests that QSM has predictive sensitivity to detect changes in clinical severity many months prior to overt cognitive involvement in Parkinson’s. However, it also suggests that susceptibility within brain tissue over time may relate to changes in tissue composition other than iron concentration, such as in the relative proportion of myelin. Whilst our findings open the door for QSM to detect patients at the earliest stages of Parkinson’s dementia, we will require additional tissue metrics to augment the interpretation QSM, such that it can be used robustly in clinical practice or to provide outcome measures in therapeutic trials for disease modifying treatments in neurodegeneration.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This research was funded in whole, or in part, by the Wellcome Trust (Ref: 205167/Z/16/Z). G.E.C.T. is supported by a PhD studentship from the Medical Research Council (Ref: MR/N013867/1). NH is supported by the Rosetrees Trust. A.Z. is supported by an Alzheimer's Research UK Postdoctoral Research Fellowship (Ref: CRF2021B-001). KS is supported by ERC consolidator grant DiSCo MRI SFN (Ref: 770939). R.S.W. is supported by a Wellcome Clinical Research Career Development Fellowship (Ref: 205167/Z/16/Z). Recruitment to the study was also supported by Parkinson's UK, the Cure Parkinson's Trust. The study was further supported by a University College London Hospitals Biomedical Research Centre Grant (Ref: BRC302/NS/RW/101410) and by grants from the National Institute for Health Research.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

All participants gave written informed consent, and the study was approved by the Queen Square Research Ethics Committee (15.LO.0476).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Data Availability

Code for running group-level analysis will be available upon full publication of the manuscript. Anonymised group-level data may be available upon request.

  • Abbreviations

    NBM
    nucleus basalis of Meynert;
    QSM
    quantitative susceptibility mapping;
    SN
    substantia nigra;
    SNpc
    substantia nigra pars compacta;
    SNpr
    substantia nigra pars reticulata;
    VBM
    voxel based morphometry;
  • Copyright 
    The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
    Back to top
    PreviousNext
    Posted July 12, 2023.
    Download PDF

    Supplementary Material

    Data/Code
    Email

    Thank you for your interest in spreading the word about medRxiv.

    NOTE: Your email address is requested solely to identify you as the sender of this article.

    Enter multiple addresses on separate lines or separate them with commas.
    Magnetic susceptibility is predictive of future clinical severity in Parkinson’s disease
    (Your Name) has forwarded a page to you from medRxiv
    (Your Name) thought you would like to see this page from the medRxiv website.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Share
    Magnetic susceptibility is predictive of future clinical severity in Parkinson’s disease
    George EC Thomas, Naomi Hannaway, Angelika Zarkali, Karin Shmueli, Rimona S Weil
    medRxiv 2023.07.12.23292555; doi: https://doi.org/10.1101/2023.07.12.23292555
    Twitter logo Facebook logo LinkedIn logo Mendeley logo
    Citation Tools
    Magnetic susceptibility is predictive of future clinical severity in Parkinson’s disease
    George EC Thomas, Naomi Hannaway, Angelika Zarkali, Karin Shmueli, Rimona S Weil
    medRxiv 2023.07.12.23292555; doi: https://doi.org/10.1101/2023.07.12.23292555

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    Subject Area

    • Radiology and Imaging
    Subject Areas
    All Articles
    • Addiction Medicine (349)
    • Allergy and Immunology (668)
    • Allergy and Immunology (668)
    • Anesthesia (181)
    • Cardiovascular Medicine (2648)
    • Dentistry and Oral Medicine (316)
    • Dermatology (223)
    • Emergency Medicine (399)
    • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (942)
    • Epidemiology (12228)
    • Forensic Medicine (10)
    • Gastroenterology (759)
    • Genetic and Genomic Medicine (4103)
    • Geriatric Medicine (387)
    • Health Economics (680)
    • Health Informatics (2657)
    • Health Policy (1005)
    • Health Systems and Quality Improvement (985)
    • Hematology (363)
    • HIV/AIDS (851)
    • Infectious Diseases (except HIV/AIDS) (13695)
    • Intensive Care and Critical Care Medicine (797)
    • Medical Education (399)
    • Medical Ethics (109)
    • Nephrology (436)
    • Neurology (3882)
    • Nursing (209)
    • Nutrition (577)
    • Obstetrics and Gynecology (739)
    • Occupational and Environmental Health (695)
    • Oncology (2030)
    • Ophthalmology (585)
    • Orthopedics (240)
    • Otolaryngology (306)
    • Pain Medicine (250)
    • Palliative Medicine (75)
    • Pathology (473)
    • Pediatrics (1115)
    • Pharmacology and Therapeutics (466)
    • Primary Care Research (452)
    • Psychiatry and Clinical Psychology (3432)
    • Public and Global Health (6527)
    • Radiology and Imaging (1403)
    • Rehabilitation Medicine and Physical Therapy (814)
    • Respiratory Medicine (871)
    • Rheumatology (409)
    • Sexual and Reproductive Health (410)
    • Sports Medicine (342)
    • Surgery (448)
    • Toxicology (53)
    • Transplantation (185)
    • Urology (165)